Frontiers in Oncology (Jan 2022)
A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients
- Min Yang,
- Min Yang,
- Min Yang,
- Bide Zhao,
- Jinghan Wang,
- Jinghan Wang,
- Jinghan Wang,
- Yi Zhang,
- Yi Zhang,
- Yi Zhang,
- Chao Hu,
- Chao Hu,
- Chao Hu,
- Lixia Liu,
- Jiayue Qin,
- Feng Lou,
- Shanbo Cao,
- Chengcheng Wang,
- Wenjuan Yu,
- Wenjuan Yu,
- Wenjuan Yu,
- Hongyan Tong,
- Hongyan Tong,
- Hongyan Tong,
- Haitao Meng,
- Haitao Meng,
- Haitao Meng,
- Jian Huang,
- Jian Huang,
- Jian Huang,
- Honghu Zhu,
- Honghu Zhu,
- Honghu Zhu,
- Jie Jin,
- Jie Jin,
- Jie Jin
Affiliations
- Min Yang
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Min Yang
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Min Yang
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Bide Zhao
- Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
- Jinghan Wang
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Jinghan Wang
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Jinghan Wang
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Yi Zhang
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Yi Zhang
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Yi Zhang
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Chao Hu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Chao Hu
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Chao Hu
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Lixia Liu
- Acornmed Biotechnology Co., Ltd., Beijing, China
- Jiayue Qin
- Acornmed Biotechnology Co., Ltd., Beijing, China
- Feng Lou
- Acornmed Biotechnology Co., Ltd., Beijing, China
- Shanbo Cao
- Acornmed Biotechnology Co., Ltd., Beijing, China
- Chengcheng Wang
- Acornmed Biotechnology Co., Ltd., Beijing, China
- Wenjuan Yu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Wenjuan Yu
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Wenjuan Yu
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Hongyan Tong
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Hongyan Tong
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Hongyan Tong
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Haitao Meng
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Haitao Meng
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Haitao Meng
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Jian Huang
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Jian Huang
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Jian Huang
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Honghu Zhu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Honghu Zhu
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Honghu Zhu
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- Jie Jin
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Jie Jin
- Institute of Hematology, Zhejiang University, Hangzhou, China
- Jie Jin
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.783114
- Journal volume & issue
-
Vol. 11
Abstract
Core Binding Factor (CBF)-AML is one of the most common somatic mutations in acute myeloid leukemia (AML). t(8;21)/AML1-ETO-positive acute myeloid leukemia accounts for 5-10% of all AMLs. In this study, we consecutively included 254 AML1-ETO patients diagnosed and treated at our institute from December 2009 to March 2020, and evaluated molecular mutations by 185-gene NGS platform to explore genetic co-occurrences with clinical outcomes. Our results showed that high KIT VAF(≥15%) correlated with shortened overall survival compared to other cases with no KIT mutation (3-year OS rate 26.6% vs 59.0% vs 69.6%, HR 1.50, 95%CI 0.78-2.89, P=0.0005). However, no difference was found in patients’ OS whether they have KIT mutation in two or three sites. Additionally, we constructed a risk model by combining clinical and molecular factors; this model was validated in other independent cohorts. In summary, our study showed that c-kit other than any other mutations would influence the OS in AML1-ETO patients. A proposed predictor combining both clinical and genetic factors is applicable to prognostic prediction in AML1-ETO patients.
Keywords
